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Abstract
Systematic reviews and meta-analyses are increasingly common. This article aims to provide guidance for people conducting
systematic reviews relevant to the healthcare of older people. An awareness of these issues will also help people reading
systematic reviews to determine whether the results will inﬂuence their clinical practice. It is essential that systematic reviews
are performed by a team which includes the required technical and clinical expertise. Those performing reviews for the ﬁrst
time should ensure they have appropriate training and support. They must be planned and performed in a transparent and
methodologically robust way: guidelines are available. The protocol should be written—and if possible published—before
starting the review. Geriatricians will be interested in a table of baseline characteristics, which will help to determine if the
studied samples or populations are similar to their patients. Reviews of studies of older people should consider how they
will manage issues such as different age cut-offs; non-speciﬁc presentations; multiple predictors and outcomes; potential
biases and confounders. Systematic reviews and meta-analyses may provide evidence to improve older people’s care, or
determine where new evidence is required. Newer methodologies, such as meta-analyses of individual level data, network
meta-analyses and umbrella reviews, and realist synthesis, may improve the reliability and clinical utility of systematic
reviews.
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Introduction
Systematic reviews and meta-analyses are increasingly com-
mon, with probably more systematic reviews than new ran-
domised trials now published every year [1]. Medline has
indexed at least 227,334 articles as ‘systematic reviews’,
increasing more than 3-fold in the last decade (from 7,579
in 2006 to 24,517 in 2015). The increase in the number of
meta-analyses has been even steeper [1]. The proportion of
these systematic reviews speciﬁcally indexed in Medline as
including participants over age 65 has remained fairly static
at around 8% (593 [7.8%] in 2006; 1846 [7.5%] in 2015),
but this is likely to be a gross underestimate since many sys-
tematic reviews do not get indexed with speciﬁc age ranges,
and most reviews include individuals regardless of age.
Clinical trials in the same period increased less steeply—
from 27,125 in 2006 to 34,270 in 2015. The attraction of
systematic reviews and meta-analyses is clear: the increasing
number and complexity of primary research studies makes
it challenging for researchers—or clinicians—to be aware
of, assimilate and critically evaluate all the available
evidence.
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A good systematic review will not only identify the pub-
lished and unpublished literature on a speciﬁc question, but
summarise the ﬁndings, critically appraise the included stud-
ies, and make recommendations on how this should inﬂu-
ence clinical practice and future research. It may or may not
include a meta-analysis (a statistical summary of the evidence).
This is a key step in reducing research waste (http://blogs.bmj.
com/bmj/2015/10/29/how-systematic-reviews-can-reduce-
waste-in-research). However, many published reviews and
meta-analyses are redundant, misleading or serve conﬂicting
interests [1], and may compound the limitations of primary
studies, rather than critically exposing them [2]. This article
aims to provide guidance for people conducting systematic
reviews relevant to the healthcare of older people, while
acknowledging that there is no universal deﬁnition of ‘older
person’. An awareness of these issues will also help people
reading systematic reviews to determine whether the results
will inﬂuence their clinical practice.
Guidance on conducting a systematic
review
Protocols
Before performing a systematic review, the reviewer
should ﬁrst ensure that the question has not already been
answered, and check whether a review is already ongoing else-
where. To check for published reviews, one can search data-
bases which collate systematic reviews and meta-analyses (e.g.
https://discover.dc.nihr.ac.uk/portal/search/signals), the
Cochrane Library (http://www.cochranelibrary.com/) or bib-
liographic databases such as Medline, PsycInfo or CINAHL.
Databases e.g. PROSPERO (https://www.crd.york.ac.uk/
PROSPERO/) are available to register a planned review.
PROSPERO is an open access resource that does not pro-
vide critical review of protocols, but provides a searchable
repository to check if this review is already complete, ongoing
or planned. Once the new protocol is ﬁnalised, it would be
useful to register it if possible. PROSPERO only allows regis-
tration of topics related to health outcomes. Other databases
e.g. http://www.researchregistry.com/ allow registration of
systematic reviews on any topic, at any stage in the review
process. The protocol can be updated later to make clear any
subsequent changes.
Practical advice
Detailed guidance on performing systematic reviews is
available elsewhere (https://www.york.ac.uk/crd/guidance/).
We have suggested some good practice points (Figure 1).
The PRISMA-P [3] and PRISMA [4] statements provide
guidance for designing and reporting systematic reviews,
respectively. A checklist is also available of what should be
included. The Cochrane Handbook of systematic reviews of
interventions [5] provides comprehensive guidance on all
aspects of systematic reviews and meta-analysis, and online
modules are freely available from Cochrane Training (http://
training.cochrane.org). This advice is most relevant for ran-
domised controlled trials (RCTs) of interventions in health-
care, e.g. pharmacological treatments such as thrombolysis in
acute ischaemic stroke [6] or complex interventions such as
multi-component interventions to prevent delirium [7].
However, much research relevant to older people is not
in the form of randomised controlled trials: this may be
due to the difﬁcultly of performing RCTs for the questions
of interest to specialists in the care of older people, encom-
passing complex multidisciplinary, multi-component inter-
ventions (e.g. stroke units) where it is not easy to tease out
the individual components. The population of interest typ-
ically includes frail older people with multiple medical con-
ditions and ranges of functional impairment, thus there is
very large heterogeneity, and the restricted eligibility criteria
of RCTs may leave out many types of patients and settings.
Where RCTs are not possible, feasible or ethical, observa-
tional study designs (cohort or case–control studies) may
provide some evidence for healthcare interventions. For a
discussion, with case examples, of how observational studies
may provide moderate to (rarely) high strength evidence in
systematic reviews of healthcare interventions see [8].
Observational methods are also a main method for exploring
associations between harmful risk-factors and outcomes, e.g.
the association between obesity and dementia [9], and there
are speciﬁc aspects that should be considered [10].
Whether a systematic review is of trials, or observational
studies, the assessment of risk of bias of each included
study, and of the review overall is key. Authors should
ensure that they do not ‘sanctify results from poor studies’
[2] and include clear critical appraisal of included data.
For speciﬁc guidance on conducting systematic reviews of
observational studies see online step by step guidance
(http://www.ccace.ed.ac.uk/research/software-resources/
systematic-reviews-and-meta-analyses) and guidance for
early career researchers in epidemiology [11]. The MOOSE
guidelines [12] provide a standard for systematic reviews of
observational studies, but have not been updated since
2000. The STROBE statement (https://www.strobe-
statement.org), outlines the issues that should be considered
in the reporting of epidemiology studies. Software is available
(e.g. Covidence https://www.covidence.org/, EPPI-Reviewer,
http://community.cochrane.org/tools/review-production-
tools/eppi-reviewer/about or Rayyan—https://rayyan.qcri.
org/) which keeps all data secure remotely, and allows col-
laboration between authors in different locations: this can
facilitate independent assessment, allow accountability and
is a method to keep track of the process. It is not a substitute
for adequate training in review methodology and statistical
literacy.
Issues to consider in studies of older people
Geriatricians are well aware of the complexity of dealing
with older patients, and the paucity of evidence to guide
their practice. When performing a systematic review
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relevant to the healthcare of older people, there are some
speciﬁc issues that should be considered.
Age
There is no generally agreed criterion for deﬁnition of ‘old-
er people’. A cut-off of over 60 or 65 years is often used
(http://www.who.int/healthinfo/survey/ageingdefnolder/en/).
However, in the developed world, the syndromes most rele-
vant to geriatricians (e.g. dementia, frailty) are most common
after age 80. In other areas, such as sub-Saharan Africa, ‘older
people’ may be deﬁned as over age 50 (http://www.who.
int/healthinfo/survey/ageingdefnolder/en/index.html). It
is important to be clear which studies will be eligible for
inclusion: those with participants at all ages, or only those
which include older people. Reviewers should predetermine
how they will deal with studies, particularly randomised
controlled trials, which have different recruitment strategies
relating to age. Many studies exclude patients over a certain
age (e.g. 75 years), in which case geriatricians will be wary
about extrapolating the results to their clinical practice. If
there is no age restriction, can results be examined speciﬁc-
ally for older people (e.g. >65; 75; 85 years)? Even if older
people are recruited, is there evidence of selection bias, i.e.
are included patients different from those in routine clinical
practice? Research studies generally recruit people who are
healthier, better educated and of higher (less deprived)
socioeconomic status. It is important to include a baseline
table of participant characteristics so that readers can deter-
mine if the results are directly relevant to their own patients
Figure 1. Good practice points for performing systematic reviews and meta-analyses in ageing research.
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or extrapolations need to be made. Many studies will not
present the overall age range, with mean and SD, but
instead split the sample into age decades, or other categor-
ies. This can make it difﬁcult to compare ﬁndings between
studies—and authors of systematic reviews should attempt
to obtain original information from study authors. We
would encourage authors of individual studies to include
overall age range, mean and SD as well as reporting in cat-
egories, and to make the individual-participant data avail-
able for reuse as soon as possible. For reviews, as a
minimum, mean or median age (in years) and a description
of the distribution (standard deviation, range or inter-
quartile range) is required. If there is a wide age range, then
it is helpful to report the numbers and proportion over 65
years. Also, reviewers should consider providing informa-
tion on the numbers of the oldest participants, e.g. numbers
and proportion of those aged over 80 or 85 years.
Non-speciﬁc presentation of disease
Systematic reviews can be challenging when there is lack of
agreement on what to include as predictor or outcome vari-
ables, or the deﬁnition of participants. For example, there is
variability in what is meant by frailty [13], or ‘care home
resident’ [14]. Many studies will focus on a single predictor
or outcome. It is important to consider if this outcome is
relevant, or a ‘surrogate’ which may, or may not relate to
clinical outcomes, e.g. body sway, rather than number of
falls. In addition, although one outcome may be reported, it
is important to consider other potentially relevant out-
comes: e.g. treatments for incontinence will report the
impact on continence, but may not report whether there
were also impacts on rate of falls or cognition. It is also
important to consider how a review will deal with outcomes
which are reported inconsistently across trials (e.g. different
cognitive tests or functional assessments). How will missing
outcome data be handled? Is it missing at random, or will
missing data inﬂuence the result? Can additional informa-
tion be obtained from the primary investigators on out-
comes that are not reported? Consider contacting the
corresponding author from the original paper, or any
author whose current contact details can be found. What
impact does death of participants have on the results? It is
also important, particularly in clinical trials, to determine
whether the outcomes are those that were planned in the
original protocol [2].
Inclusion/exclusion criteria
Are the people included similar to routine clinical practice?
For example, are people excluded on the basis of age, or
co-morbidities that are common in older people? Be aware
of international variation in healthcare practices: the infra-
structure in a residential home, or support by families, var-
ies widely internationally. There is also international
variation in attitudes to ageing by older people themselves,
and others [15] which may affect the impact of
interventions. Can the ﬁndings be extrapolated to a clinical
population? If data on populations of interest (e.g. age over
90; care home residents; people lacking capacity) are lack-
ing, identify and discuss this gap in the literature.
Study design
Be clear if the studies included are intervention studies (e.g.
randomised controlled trials) or observational studies (e.g.
prospective or retrospective cohort studies, or case–control
studies), and what methodological considerations are
important for each. Note that observational designs identify
associations, but cannot prove causation: e.g. the association
between diabetes and risk of falls may be due to complica-
tions of diabetes, or hypoglycaemia, or unmeasured con-
founders such as hypotension or other unknown or
convoluted reasons [16].
Confounding
Particularly for observational studies, it is important to con-
sider if the results could be explained by another variable
that may be unobserved. Confounding variables may make
it appear—incorrectly—that an observed exposure or pre-
dictor is (or is not) causally associated with an outcome. In
studies of older people, potentially important confounders,
particularly from earlier life, should be considered, such as
socioeconomic status. For example, socioeconomic status
probably explains the observed association between caffeine
intake and IQ [17].
Effect modiﬁcation
This occurs in studies where an exposure has a different
effect in different subgroups: effect modiﬁers are associated
with the outcome, not the exposure. For example, older (or
frailer, or cognitively impaired) people may respond differ-
ently to an intervention than younger (or ﬁtter, or cogni-
tively normal) people.
Bias
Bias is an incorrect estimation of the association, e.g.
between exposure and outcome, due to a systematic error.
The assessment of bias is a critical component of systematic
reviews of RCTs and observational studies, and is the main
component of what has often been termed ‘quality assess-
ment’. Careful consideration should be given in advance as
to how studies will be assessed (see [14] for some guidance
relevant to studies of older people: including the Cochrane
Risk of Bias tool [19] for RCTs, ROBANS [18] for obser-
vational studies). Summary scores are generally discouraged
as they can mask complexity and give equal weight to
aspects of quality assessment that could have minimal, or
large, impact on the applicability of results. Note, however,
that there can be considerable inter-individual variation in
risk of bias assessments (e.g. [19]).
Systematic reviews
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For all studies including older people, reviewers should
consider selection bias—that results will be distorted by
including people in the study that are not representative of
patients that are looked after in clinical practice (e.g. the
hypertension study SPRINT which excluded people aged
≥75 with co-morbidities such as diabetes, heart failure,
stroke, dementia [20])—and survival bias—that only those
who survive are included in the results, which may give
erroneous conclusions about efﬁcacy of treatments or risk-
factors for outcomes (e.g. better function appeared to pre-
dict care home admission in this study as those with poorer
function died before discharge [21]).
Meta-analysis
A statistical synthesis of the results [22] is not required for
a systematic review (either of RCTs or observational data),
but this should be performed where possible, while being
aware of how to interpret the results in the presence of het-
erogeneity. It is good practice to contact authors of the ori-
ginal studies to obtain additional data (e.g. if data have been
presented in different age bands in different studies): this
can be variably successful. It is important to have sufﬁcient
statistical expertise in the systematic review team, and to
combine this with clinical knowledge to assess if statistical
synthesis is appropriate and how it should be interpreted. A
summary effect can be tantalisingly succinct, but this should
not dissuade authors from critically discussing the limita-
tions of the included studies and, therefore, the summary
evidence. Different meta-analyses of the same question can
come to different conclusions due to inclusion of studies
with diverse protocols and methods.
If presenting data in a forest plot, check that the axes
are clearly labelled, so that the size of the effect, and its
potential clinical signiﬁcance, can be gauged. Include conﬁ-
dence intervals of the summary estimate. Is a ﬁxed-effect
or random-effect model planned, or will a prediction inter-
val be presented: this provides a predicted range for the
true treatment effect in an individual study [19]? Reviews
often quote formal measures of heterogeneity such as the I2
statistic, but it is also important to carefully scrutinise the
table of baseline characteristics to see if there is relevant
heterogeneity between the individual studies included.
Whether meta-analysis is possible or not, systematic reviews
should narratively summarise and critically appraise the
results across all included studies.
Using systematic reviews to inform clinical
practice and service redesign
It is typically discouraged for systematic reviewers them-
selves to make ex ofﬁcio guideline-level recommendations.
Usually, systematic reviews end with the critical appraisal
and synthesis of the evidence. However, these systematic
reviews are used eventually by multiple users, ranging from
clinical practitioners and readers to guideline committees to
inform clinical practice and for service redesign. Systematic
reviews have been helpful to prompt changes in clinical
practice, when change has not followed publication of indi-
vidual trials (e.g. thrombolysis for acute ischaemic stroke).
Reviews can also be used to support business cases for ser-
vice redesign (e.g. comprehensive geriatric assessment) or to
identify gaps in evidence where research and clinical change
is required (e.g. music therapy in the acute hospital). When
assessing the relevance of the review to the care of older
people, readers should consider the quality of the systematic
review itself as well as the studies that are included in it.
Are included subjects relevant to clinical practice? Is the
intervention feasible in routine care? Tools such as
AMSTAR [23] suggest items which should be considered in
determining quality of a published systematic review.
The future of systematic reviews and meta-
analysis
Given the limitations of published reviews and meta-
analyses, it is essential that clinicians treat the results with
appropriate scepticism, and make informed choices for any
proposed change in practice. Although systematic reviews
and meta-analyses may be seen as the ‘top’ of the evidence
pyramid, this only applies if the reviews are performed to
the highest standard. The quality of reporting of published
reviews has improved since the publication of the PRISMA
statement [4], but the large majority of reviews and meta-
analyses continue to be ﬂawed, redundant, misleading or
clinically not useful [1]. The requirement that authors dis-
close any conﬂict of interest is important: results and con-
clusions are often biased when authored by company
employees, or if a study is industry sponsored [24].
Crucially, there is an increasing call from funders as well as
researchers that all clinical trials (and observational studies)
are reported (e.g. www.AllTrials.net) and that individual
level data is made available as soon as possible. This
requires additional infrastructure and funding, especially for
studies that require signiﬁcant storage space such as
imaging data (e.g. Alzheimer’s Disease Neuroimaging
Initiative http://adni.loni.usc.edu/).
There are several methodologies which may improve the
reliability and clinical utility of systematic reviews [1], and
these are discussed here.
Individual patient meta-analysis
Where the data from individual studies are combined (while
retaining the clustering of patients within their individual
study)—has become increasingly common [25]. It is often
limited by the provision of original data, and may result in
analysis of only a subset of otherwise eligible studies, and
thus can be prone to reporting bias. The meta-analysis of
data across multiple observational studies can allow a sum-
mary estimate of risk-factors, e.g. the effect of smoking and
smoking cessation on cardiovascular mortality in older peo-
ple [26], but is still at risk of residual confounding. Selection
S. D. Shenkin et al.
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for inclusion of studies based on already known results can
be a problem in meta-analyses of individual level data [27].
Network meta-analysis
Network meta-analysis allows multiple treatments to be com-
pared using direct comparisons within randomised controlled
trials and indirect comparisons using a common comparator
[28]. This allows both direct and indirect evidence to be used
to synthesise the published evidence, such as the effective-
ness and adverse effects of antidepressants [29]. Treatment
networks can quantitatively analyse data for all treatment
comparisons for the same disease. Multiple treatments meta-
analysis can rank the effectiveness of many treatments in a
network. However, for this to add useful information to sim-
pler methods of data synthesis, large amounts of data are
required, and care must be taken in interpretation of the dir-
ect and indirect comparisons, which can sometimes disagree.
Prospective meta-analysis
Trials can be designed with the explicit predeﬁned purpose
of future combination in a meta-analysis [2]: this approach
can combine studies with different designs, interventions,
comparisons, setting and populations. It is ideal for diverse
interventions such as falls prevention programmes [30], but
is uncommon as they require signiﬁcant collaboration, co-
ordination and advance planning.
Umbrella reviews [2] are systematic reviews of systematic
reviews: they may summarise all systematic reviews or
meta-analyses performed on a given topic, e.g. all treat-
ments for a condition or set of conditions; or all risk-
factors assessed for some disease (e.g. Alzheimer’s disease,
[31]); or all associations that a speciﬁc risk factor has been
evaluated for in relationship to a variety of outcomes/dis-
eases (e.g. [32]). These reviews may permit understanding
of the amount and credibility of the evidence in a large
ﬁeld, knowledge gaps and the main sources of heterogen-
eity and bias.
Rapid reviews [33] are gaining popularity as methods to
make reviews and subsequent treatment decisions more
rapidly than allowed by full systematic reviews. If appropri-
ately supervised they may be useful for training, and may
markedly speed up the review process, but as yet there is
no consensus on deﬁnition or methodology. Similarly, par-
ticipation in adjudication of studies for systematic reviews
as in Cochrane Crowd (http://crowd.cochrane.org) can
provide some experience and training. Cochrane crowd are
not a substitute for a systematic review by a team with
appropriate expertise.
Realist synthesis
Realist synthesis has been suggested as a pragmatic
approach for evaluating complex interventions [34] e.g.
models of care for older people living in care homes [35]. It
tries to establish, ‘what works for whom in what circum-
stances and in what respects?’ [36], rather than looking at
single interventions. However, the lack of predeﬁned ques-
tions/outcomes risks focussing on positive studies, and it
may be most useful as an exploratory method for complex
and multidisciplinary interventions.
Conclusions
Despite their limitations, systematic reviews are useful for
practising geriatricians to inform clinical care, and to iden-
tify where further research is needed. It is essential that any
review, either using traditional or more novel methodolo-
gies, is done to a high standard, considering both general
issues for good quality reporting, but also paying particular
attention to speciﬁc issues relevant to the health of older
people.
Key points
• Systematic reviews must be planned and performed in a
transparent and methodologically robust way: guidelines
are available, and a carefully designed protocol will help.
• A table of baseline characteristics will help practising geria-
tricians in relating the studied populations to their patients.
• Geriatricians should consider how reviews deal with: differ-
ent age cut-offs; non-speciﬁc presentations; multiple predic-
tors and outcomes; potential biases and confounders.
• Reviews may determine where new evidence is required
to improve the care of older people.
• Meta-analyses of individual level data, network meta-
analyses and umbrella reviews offer interesting possibil-
ities for more in-depth or broader views of the evidence.
Supplementary data
Supplementary data are available at Age and Ageing online.
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